Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reversing antibiotic resistance.

Rebecca Hodgkinson, Derek Sharples

    Expert Opinion on Investigational Drugs
    |August 2, 2002
    PubMed
    Summary
    This summary is machine-generated.

    Chemotherapy effectiveness is declining due to multi-drug resistance, often caused by P-glycoprotein efflux pumps. Researchers are seeking new drugs and resistance reversal agents to combat this challenge.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Neither Small Adults nor Big Children: Doing Better for TYAs with Brain Tumors.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2025
    Same author

    The mechanism of plasmid curing in bacteria.

    Current drug targets·2006
    Same author

    The interaction between resistance modifiers such as pyrido[3,2-g]quinoline, aza-oxafluorene and pregnane derivatives with DNA, plasmid DNA and tRNA.

    European journal of medicinal chemistry·2005
    Same author

    Synthesis of 9-acridinyl sulfur derivatives: sulfides, sulfoxides and sulfones. Comparison of their activity on tumour cells.

    European journal of medicinal chemistry·2004
    Same author

    Stresses and coping strategies of mothers living with a child with cystic fibrosis: implications for nursing professionals.

    Journal of advanced nursing·2002
    Same author

    Antiproliferative amaryllidaceae alkaloids isolated from the bulbs of Sprekelia formosissima and Hymenocallis x festalis.

    Planta medica·2002
    Same journal

    Advancements in longevity pharmacology research - are we finally seeing clinical progression?

    Expert opinion on investigational drugs·2026
    Same journal

    Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

    Expert opinion on investigational drugs·2026
    Same journal

    Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

    Expert opinion on investigational drugs·2026
    Same journal

    Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

    Expert opinion on investigational drugs·2026
    Same journal

    Odronextamab: a bispecific antibody for follicular lymphoma.

    Expert opinion on investigational drugs·2026
    Same journal

    Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

    Expert opinion on investigational drugs·2026
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology
    • Molecular Biology

    Background:

    • Chemotherapeutic agents are losing effectiveness over the last decade.
    • Multi-drug resistance (MDR) is a significant challenge in cancer treatment.
    • Increased activity of P-glycoprotein efflux pumps is a primary cause of MDR.

    Discussion:

    • The study addresses the critical issue of acquired resistance to established chemotherapeutic drugs.
    • It highlights the role of P-glycoprotein in mediating multi-drug resistance through enhanced efflux pump activity.
    • The findings underscore the urgent need for novel therapeutic strategies.

    Key Insights:

    • P-glycoprotein-mediated efflux is a key mechanism driving chemotherapy resistance.
    • Existing chemotherapeutic drugs are becoming less effective against resistant cancer cells.

    Related Experiment Videos

  • Developing agents to overcome MDR is crucial for improving patient outcomes.

    • Outlook:

    • Continued research into novel chemotherapeutic agents is essential.
    • Focus on identifying compounds that can reverse P-glycoprotein-mediated resistance.
    • Future therapies may combine traditional chemotherapy with resistance-modulating agents.